ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Visceral leishmaniasis: Epidemiology and control

Visceral leishmaniasis: Epidemiology and control
Literature review current through: Jan 2024.
This topic last updated: Nov 21, 2023.

INTRODUCTION — Leishmaniasis consists of a complex of vector-borne diseases caused by more than 20 species of the protozoan genus Leishmania and is transmitted by sand fly vectors (table 1) [1,2]. Clinical manifestations range from cutaneous ulcers to systemic multiorgan disease. Visceral leishmaniasis (VL) is caused primarily by the two related species Leishmania donovani and Leishmania infantum (synonym Leishmania chagasi).

Issues related to epidemiology and control are discussed here. Issues related to clinical manifestations, diagnosis, and treatment are discussed separately. (See "Visceral leishmaniasis: Clinical manifestations and diagnosis" and "Visceral leishmaniasis: Treatment".)

EPIDEMIOLOGY — The epidemiology and ecology of VL in a particular region are determined by characteristics of the parasite species, sand fly species, and mammalian reservoir host(s) (figure 1). In all major endemic areas, asymptomatic infections (measured by seroconversion and/or leishmanin skin testing) outnumber clinically manifest disease [3-6]. Seroconversion reflects newly acquired infection but may precede onset of clinical VL by months [4,5].

Close to 12,000 incident cases of VL were reported to the World Health Organization (WHO) in 2021 [7,8]; these figures are thought to represent a substantial underestimate, especially in Africa. Among tropical diseases, leishmaniasis ranks second in mortality and seventh in loss of disability-adjusted life years (DALYs) [9,10]. Leishmaniasis is considered one of the "most neglected diseases" given its strong association with poverty and the limited resources invested in new tools for diagnosis, treatment, and control [11,12].

The best measure of protective immunity is the leishmanin skin test (LST), which reflects durable but probably not permanent cell-mediated immunity. No standardized leishmanin antigen is available, but efforts are underway to develop such a reagent, with a focus on its potential use as an outcome measure in vaccine trials [13]. In observational studies, individuals with positive LST have more than 95 percent reduced risk of VL compared with those with negative LST, and the age-related rise in positive LST prevalence in a community parallels the age-related decrease in disease risk [6,14-16]. A parallel fall in the average age of VL patients may be observed as an epidemic matures [17]. Factors that increase the likelihood an individual will progress from leishmanial infection to clinical VL include poor nutritional status, age <5 years (for L. infantum infection), HIV coinfection, and host immunogenetic factors [15,18-22].

Species

L. donovani — Visceral leishmaniasis due to L. donovani occurs in South Asia (India, Bangladesh, and Nepal) and East Africa (Sudan, South Sudan, Ethiopia, Eritrea, Kenya, Uganda, and Somalia). Clinical disease due to L. donovani can affect individuals of all ages, although, in regions with sustained endemic transmission, the incidence may fall with increasing age because of a high rate of acquired immunity in adults [1,14].

In both the Indian subcontinent and East Africa, VL tends to occur in epidemic cycles; the incidence rises over a period of 2 to 5 years, peaks, and then falls, only to rise again after a 5- to 20-year period of low incidence [23,24]. In 2014, India and Bangladesh together reported approximately 10,000 VL cases, while Sudan, South Sudan, and Ethiopia together reported more than 14,000 cases [23]. The true case load was likely substantially higher.

In northeastern India, southeastern Nepal, and Bangladesh, efforts to eliminate VL (particularly L. donovani transmission) as a public health problem have been underway since 2005. Areas of emphasis have included improving timeliness and effectiveness of diagnosis and treatment as well as vector control through residual household insecticide application. In this area of transmission, humans are the only proven reservoir host [1,25-27]. Diagnosis with rapid tests and treatment with single dose liposomal amphotericin B 10 mg/kg at primary health care facilities in endemic areas have been crucial in decreasing the human infection reservoir [28]. Criteria for validation of elimination as a public health problem include maintenance of VL incidence below 1 per 10,000 population at the subdistrict (Bangladesh), block (India) or district (Nepal) level for at least 3 years, and documentation of all components of the elimination program, including sustained sensitive surveillance [29]. The incidence of VL has fallen markedly between 2005 and 2022 in all three countries [23,28,30-33]. In October 2023, Bangladesh received official validation of elimination of VL as a public health problem from the WHO; incidence has been below the elimination threshold since 2017 [34]. In Nepal, the incidence threshold has been reached, but in recent years VL cases are being reported from hilly districts not previously considered endemic, where control efforts had not been instituted and diagnosis and treatment are less accessible, presenting challenges to the elimination program [35]. Climate change is widely hypothesized to play a role. In India, only one block reported incidence above 1 per 10,000 in 2022 [36]. Efforts are underway to develop practical methods to sustain adequate surveillance in the face of very low incidence [37-39].

In East Africa, transmission of L. donovani consists of both anthroponotic and zoonotic components. In Sudan, sylvatic rodents and domestic dogs may act as reservoirs; however, large human VL outbreaks in villages and refugee settings are thought to reflect predominantly anthroponotic transmission [17,40-44]. With the marked decline in the number of VL cases in the Indian subcontinent, East Africa is now the region with the highest caseload globally [45]. There are now calls for a more concerted effort to control VL in East Africa, building on the lessons of the elimination programs in the Indian subcontinent [46,47].

L. infantum — VL due to L. infantum (synonym L. chagasi) occurs in the Mediterranean (including Spain, France, and Greece), the Middle East, Afghanistan, Iran, Pakistan, and Brazil. In addition, sporadic cases have been reported in Central Asia, China, Mexico, and Central and Latin America outside of Brazil [2,25].

In 2021, the highest L. infantum VL case load was reported from Brazil with 1492 cases [23]. Aside from Yemen where both L. donovani and L. infantum have been reported [48], all other L. infantum–endemic countries reported fewer than 100 human cases in 2021 [8].

Children <10 years and immunosuppressed adults have a higher risk of clinical disease due to L. infantum than immunocompetent adults [49-51]. The predominance of pediatric L. infantum cases may be related to several factors including lower parasite virulence than L. donovani, the immature innate immune response, lack of prior exposure and acquired immunity, and higher rates of malnutrition among children than adults [6,18,52]. The lower incidence of L. infantum among adults in endemic areas may be due in part to prior exposure resulting in cell-mediated immunity [6,14,53,54].

In one study including 200 United States soldiers deployed to Iraq between 2002 and 2011, 19.5 percent had at least one test positive for probable asymptomatic L. infantum infection (1 percent by polymerase chain reaction, 5 percent by serology, and 14 percent by interferon-gamma release assays) [55]. In another study of United States soldiers deployed to Iraq or Afghanistan from 2001 to 2016, 25 symptomatic cases of VL due to L. infantum were reported [56].

L. infantum is zoonotic, with infected domestic and feral dogs forming the primary reservoir in most geographic locations (figure 2) [1,2,25]. However, multiple other mammalian species, including foxes, raccoon-dogs, and jackals, can be infected with L. infantum, and a large outbreak in a suburb of Madrid was fueled by infection in hares [2,57-59]. Because of the zoonotic reservoirs, L. infantum transmission can be maintained in the absence of human VL cases.

Transmission — VL sand fly vectors include more than 10 species of the genus Phlebotomus (in the Old World) and Lutzomyia longipalpis (in the New World) [1,2]. The female sand fly is hematophagous; both sexes take sugar meals from plant sources. Important sand fly characteristics that vary by species include breeding sites, peak feeding times, population seasonality, preferred blood meal sources, aggregation, and resting behavior [2,60].

Leishmaniasis can also be transmitted via intravenous drug use, blood transfusion, organ transplantation, congenital infection, and laboratory accidents [61-66]. These modes of transmission are rare.

CONTROL — Control of VL is based on two major approaches: vector control to decrease sand fly bites among humans and management of infected humans and animals to decrease the infection reservoir.

Vector control — Sand flies have a relatively limited flight range, and, in areas where transmission is predominantly sylvatic, it may be possible to establish vegetation-free buffer zones around human dwellings [67,68]. In the major domestic transmission foci, interventions tend to focus on barrier methods such as bed nets and screens and insecticide application on surfaces where the flies rest. Thorough understanding of vector behavior is essential to design effective control strategies [67]. Vector control modalities include indoor residual insecticide spraying (IRS), insecticide-treated nets (ITNs), and other applications of insecticides or repellents to decrease sand fly biting.

In areas where sand flies rest inside human dwellings, IRS every six months may be an effective intervention, although it is costly due to the infrastructure, equipment, and training required. Effective supervision is required to ensure the appropriate use of materials and to prevent diversion for agricultural applications. IRS conducted for malaria eradication in the Indian subcontinent during the 1950s and 1960s nearly eliminated VL, though a major resurgence occurred within a decade following the end of the program [69,70]. Major efforts have been made to evaluate and improve IRS programs in the Indian subcontinent [71,72]. The effectiveness of the Indian IRS program is still a matter of debate, in part because the vector appears to be more exophilic than previously thought [73,74]. (See "Malaria: Epidemiology, prevention, and control", section on 'Indoor residual spraying'.)

Insecticide-treated bed nets may be effective in regions such as South Asia, where the peak period of vector activity is late in the evening [75-77]. However, a cluster-randomized trial of insecticide-treated nets failed to demonstrate a significant decrease in clinical VL and VL infection in sites in India and Nepal [78], and decreases in indoor vector density were smaller than anticipated [79]. Reasons for this failure are poorly understood but may be related to acquired insecticide resistance and changes in vector behavior (eg, from indoor to outdoor biting and resting) in response to insecticide pressure from poorly implemented indoor residual spray programs [74]. Long-lasting insecticide-treated nets appear to maintain efficacy based on standard laboratory bioassays for at least two years under field conditions in South Asia [80]. Limitations include the importance of regular use and that those at highest risk for VL are the least likely to obtain the materials successfully.

Treated dog collars are a promising tool for vector control in areas of zoonotic VL [81].

Use of insect repellent and insecticide-treated clothing is advisable for travelers [82] but, in general, is not a practical routine intervention for residents of endemic areas. (See "Prevention of arthropod and insect bites: Repellents and other measures".)

Reservoir hosts — Rapid diagnosis and effective treatment of anthroponotic VL helps decrease the human reservoir of infection [83]. Patients with post-kala-azar dermal leishmaniasis (PKDL) are an especially important reservoir of infection for a number of reasons; PKDL can persist for years, PKDL treatment requires a prolonged course of therapy, and such patients are less likely to seek care than those with kala-azar [84-86]. Both VL and PKDL patients were shown to be infective to sand flies in xenodiagnosis studies conducted during the 1920s and 1930s [87,88]. More recent studies confirm the infectivity of PKDL patients [89,90]. Timely, improved detection, diagnosis, and treatment of PKDL will be essential to maintaining improved control of VL in India, Bangladesh, and Nepal [37].

Programs focusing on reduction of canine reservoirs to decrease zoonotic VL transmission have not proved highly effective. This may be due to inadequate diagnostic sensitivity to identify infectious dogs, delay between diagnosis and culling, and the finding that most of the sand fly infections derive from a small percentage of highly infectious dogs (superspreaders) [91,92]. Manipulations of animal populations may have unexpected consequences depending on host density and role (as infection reservoir, blood meal source for sand flies, and/or nonsusceptible host) [2,87,93].

SUMMARY

Species – Visceral leishmaniasis (VL) is caused primarily by the two related species Leishmania donovani and Leishmania infantum (synonym Leishmania chagasi). (See 'Introduction' above and 'Species' above.)

L. donovani – VL due to L. donovani occurs in South Asia (India, Bangladesh, and Nepal) and the Horn of Africa (Sudan, Ethiopia, Kenya, and Somalia). Clinical disease due to L. donovani affects all ages, including otherwise healthy adults. In the Indian subcontinent, L. donovani transmission is anthroponotic; humans are the only proven reservoir host. In East Africa, both anthroponotic and zoonotic L. donovani transmission occur. (See 'L. donovani' above.)

L. infantum VL due to L. infantum (synonym L. chagasi) occurs in the Mediterranean, the Middle East, Afghanistan, Iran, Pakistan, and Brazil. In addition, sporadic cases have been reported in Central Asia, China, Mexico, and Central and Latin America outside of Brazil. In general, clinical disease due to L. infantum is more likely to occur in children <10 years and immunosuppressed adults. L. infantum transmission is zoonotic; the major reservoir for L. infantum infection is the domestic dog. (See 'L. infantum' above.)

Transmission – VL sand fly vectors include more than 10 species of the genus Phlebotomus (in the Old World) and Lutzomyia longipalpis (in the New World). VL can also be transmitted via intravenous drug use, blood transfusion, organ transplantation, congenital infection, and laboratory accidents; these modes of transmission are rare. (See 'Transmission' above.)

Prevention and control - Control of VL is based on two major approaches: vector control to decrease sand fly bites among humans and management of infected humans and animals to decrease the infection reservoir. (See 'Control' above.)

  1. Jeronimo SMB, de Queiroz Sousa A, Pearson RD. Leishmaniasis. In: Tropical Infectious Diseases: Principles, Pathogens and Practice, 3rd ed, Guerrant RL, Walker DH, Weller PF (Eds), Saunders Elsevier, Philadelphia 2011. p.696.
  2. World Health Organization. Control of the Leishmaniases: Report of the WHO Expert Committee Meeting, Geneva. March 22-26, 2010. WHO Technical Report Series 2010; 949:1.
  3. Marty P, Lelievre A, Quaranta JF, et al. Use of the leishmanin skin test and western blot analysis for epidemiological studies in visceral leishmaniasis areas: experience in a highly endemic focus in Alpes-Maritimes (France). Trans R Soc Trop Med Hyg 1994; 88:658.
  4. Hasker E, Malaviya P, Gidwani K, et al. Strong association between serological status and probability of progression to clinical visceral leishmaniasis in prospective cohort studies in India and Nepal. PLoS Negl Trop Dis 2014; 8:e2657.
  5. Bern C, Haque R, Chowdhury R, et al. The epidemiology of visceral leishmaniasis and asymptomatic leishmanial infection in a highly endemic Bangladeshi village. Am J Trop Med Hyg 2007; 76:909.
  6. Lima ID, Queiroz JW, Lacerda HG, et al. Leishmania infantum chagasi in northeastern Brazil: asymptomatic infection at the urban perimeter. Am J Trop Med Hyg 2012; 86:99.
  7. Global leishmaniasis surveillance: 2019–2020, a baseline for the 2030 roadmap. Geneva: World Health Organization. 2020. https://www.who.int/publications/i/item/who-wer9635-401-419 (Accessed on December 17, 2021).
  8. Global Health Observatory data repository. Number of cases of visceral leishmaniasis reported, Data by country. https://apps.who.int/gho/data/node.main.NTDLEISHVNUM (Accessed on April 05, 2023).
  9. GBD 2015 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016; 388:1603.
  10. GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016; 388:1459.
  11. Yamey G, Torreele E. The world's most neglected diseases. BMJ 2002; 325:176.
  12. Alvar J, Yactayo S, Bern C. Leishmaniasis and poverty. Trends Parasitol 2006; 22:552.
  13. Pacheco-Fernandez T, Volpedo G, Gannavaram S, et al. Revival of Leishmanization and Leishmanin. Front Cell Infect Microbiol 2021; 11:639801.
  14. Bern C, Amann J, Haque R, et al. Loss of leishmanin skin test antigen sensitivity and potency in a longitudinal study of visceral leishmaniasis in Bangladesh. Am J Trop Med Hyg 2006; 75:744.
  15. Davies CR, Mazloumi Gavgani AS. Age, acquired immunity and the risk of visceral leishmaniasis: a prospective study in Iran. Parasitology 1999; 119 ( Pt 3):247.
  16. Khalil EA, Zijlstra EE, Kager PA, El Hassan AM. Epidemiology and clinical manifestations of Leishmania donovani infection in two villages in an endemic area in eastern Sudan. Trop Med Int Health 2002; 7:35.
  17. Alvar J, Bashaye S, Argaw D, et al. Kala-azar outbreak in Libo Kemkem, Ethiopia: epidemiologic and parasitologic assessment. Am J Trop Med Hyg 2007; 77:275.
  18. Cerf BJ, Jones TC, Badaro R, et al. Malnutrition as a risk factor for severe visceral leishmaniasis. J Infect Dis 1987; 156:1030.
  19. Anstead GM, Chandrasekar B, Zhao W, et al. Malnutrition alters the innate immune response and increases early visceralization following Leishmania donovani infection. Infect Immun 2001; 69:4709.
  20. Soong L, Henard CA, Melby PC. Immunopathogenesis of non-healing American cutaneous leishmaniasis and progressive visceral leishmaniasis. Semin Immunopathol 2012; 34:735.
  21. Jeronimo SM, Duggal P, Ettinger NA, et al. Genetic predisposition to self-curing infection with the protozoan Leishmania chagasi: a genomewide scan. J Infect Dis 2007; 196:1261.
  22. van Griensven J, Carrillo E, López-Vélez R, et al. Leishmaniasis in immunosuppressed individuals. Clin Microbiol Infect 2014; 20:286.
  23. Leishmaniasis in high-burden countries: an epidemiological update based on data reported in 2014. Wkly Epidemiol Rec 2016; 91:287.
  24. World Health Organization. Fact sheets: Leishmaniasis. https://www.who.int/news-room/fact-sheets/detail/leishmaniasis (Accessed on March 10, 2023).
  25. Bern C, Maguire JH, Alvar J. Complexities of assessing the disease burden attributable to leishmaniasis. PLoS Negl Trop Dis 2008; 2:e313.
  26. Singh N, Mishra J, Singh R, Singh S. Animal reservoirs of visceral leishmaniasis in India. J Parasitol 2013; 99:64.
  27. Kushwaha AK, Shukla A, Scorza BM, et al. Livestock and rodents within an endemic focus of Visceral Leishmaniasis are not reservoir hosts for Leishmania donovani. PLoS Negl Trop Dis 2022; 16:e0010347.
  28. Singh OP, Tiwary P, Kushwaha AK, et al. Xenodiagnosis to evaluate the infectiousness of humans to sandflies in an area endemic for visceral leishmaniasis in Bihar, India: a transmission-dynamics study. Lancet Microbe 2021; 2:e23.
  29. World Health Organization. Process of validation of elimination of kala-azar as a public health problem in South-East Asia. https://www.who.int/publications/i/item/sea-cd-321 (Accessed on November 15, 2023).
  30. Alvar J, Vélez ID, Bern C, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS One 2012; 7:e35671.
  31. Rijal S, Sundar S, Mondal D, et al. Eliminating visceral leishmaniasis in South Asia: the road ahead. BMJ 2019; 364:k5224.
  32. Singh OP, Sundar S. Visceral leishmaniasis elimination in India: progress and the road ahead. Expert Rev Anti Infect Ther 2022; 20:1381.
  33. World Health Organization. Bangladesh eliminates visceral leishmaniasis, Maldives interrupts leprosy transmission and DPR Korea eliminates rubella. https://www.who.int/southeastasia/news/detail/31-10-2023-bangladesh-eliminates-visceral-leishmaniasis--maldives-interrupts-leprosy-transmission-and-dpr-korea-eliminates-rubella--who#:~:text=Bangladesh%20has%20become%20the%20first,life-threatening%20neglected%20tropical%20disease (Accessed on November 08, 2023).
  34. World Health Organization. Bangladesh achieves historic milestone by eliminating kala-azar as a public health problem. https://www.who.int/news/item/31-10-2023-bangladesh-achieves-historic-milestone-by-eliminating-kala-azar-as-a-public-health-problem#:~:text=%E2%80%9CBangladesh%20is%20the%20first%20country,health%20problem%20in%20May%202023 (Accessed on November 15, 2023).
  35. Pandey K, Dumre SP, Shah Y, et al. Forty years (1980-2019) of visceral leishmaniasis in Nepal: trends and elimination challenges. Trans R Soc Trop Med Hyg 2023; 117:460.
  36. National Center for Vector Borne Diseases Control. Kala-Azar situation in India. https://ncvbdc.mohfw.gov.in/index4.php?lang=1&level=0&linkid=467&lid=3750 (Accessed on November 15, 2023).
  37. Cameron MM, Acosta-Serrano A, Bern C, et al. Understanding the transmission dynamics of Leishmania donovani to provide robust evidence for interventions to eliminate visceral leishmaniasis in Bihar, India. Parasit Vectors 2016; 9:25.
  38. Chapman LAC, Morgan ALK, Adams ER, et al. Age trends in asymptomatic and symptomatic Leishmania donovani infection in the Indian subcontinent: A review and analysis of data from diagnostic and epidemiological studies. PLoS Negl Trop Dis 2018; 12:e0006803.
  39. Bindroo J, Priyamvada K, Chapman LAC, et al. Optimizing Village-Level Targeting of Active Case Detection to Support Visceral Leishmaniasis Elimination in India. Front Cell Infect Microbiol 2021; 11:648847.
  40. Elnaiem DA, Hassan HK, Ward RD. Phlebotomine sandflies in a focus of visceral leishmaniasis in a border area of eastern Sudan. Ann Trop Med Parasitol 1997; 91:307.
  41. Bucheton B, Kheir MM, El-Safi SH, et al. The interplay between environmental and host factors during an outbreak of visceral leishmaniasis in eastern Sudan. Microbes Infect 2002; 4:1449.
  42. Seaman J, Mercer AJ, Sondorp E. The epidemic of visceral leishmaniasis in western Upper Nile, southern Sudan: course and impact from 1984 to 1994. Int J Epidemiol 1996; 25:862.
  43. Elnaiem DA, Hassan MM, Maingon R, et al. The Egyptian mongoose, Herpestes ichneumon, is a possible reservoir host of visceral leishmaniasis in eastern Sudan. Parasitology 2001; 122:531.
  44. Dereure J, El-Safi SH, Bucheton B, et al. Visceral leishmaniasis in eastern Sudan: parasite identification in humans and dogs; host-parasite relationships. Microbes Infect 2003; 5:1103.
  45. World Health Organization. Global leishmaniasis surveillance: 2019–2020, a baseline for the 2030 roadmap. Weekly Epidemiological Record, 2021, vol. 96 (35): 401-419.
  46. Alvar J, den Boer M, Dagne DA. Towards the elimination of visceral leishmaniasis as a public health problem in east Africa: reflections on an enhanced control strategy and a call for action. Lancet Glob Health 2021; 9:e1763.
  47. Dahl EH, Hamdan HM, Mabrouk L, et al. Control of visceral leishmaniasis in East Africa: fragile progress, new threats. BMJ Glob Health 2021; 6.
  48. Mahdy MA, Al-Mekhlafi AM, Abdul-Ghani R, et al. First Molecular Characterization of Leishmania Species Causing Visceral Leishmaniasis among Children in Yemen. PLoS One 2016; 11:e0151265.
  49. Evans TG, Teixeira MJ, McAuliffe IT, et al. Epidemiology of visceral leishmaniasis in northeast Brazil. J Infect Dis 1992; 166:1124.
  50. Alvar J, Aparicio P, Aseffa A, et al. The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev 2008; 21:334.
  51. Gil-Prieto R, Walter S, Alvar J, de Miguel AG. Epidemiology of leishmaniasis in Spain based on hospitalization records (1997-2008). Am J Trop Med Hyg 2011; 85:820.
  52. Dye C, Williams BG. Malnutrition, age and the risk of parasitic disease: visceral leishmaniasis revisited. Proc Biol Sci 1993; 254:33.
  53. Seaman J, Ashford RW, Schorscher J, Dereure J. Visceral leishmaniasis in southern Sudan: status of healthy villagers in epidemic conditions. Ann Trop Med Parasitol 1992; 86:481.
  54. Gramiccia M, Bettini S, Gradoni L, et al. Leishmaniasis in Sardinia. 5. Leishmanin reaction in the human population of a focus of low endemicity of canine leishmaniasis. Trans R Soc Trop Med Hyg 1990; 84:371.
  55. Mody RM, Lakhal-Naouar I, Sherwood JE, et al. Asymptomatic Visceral Leishmania infantum Infection in US Soldiers Deployed to Iraq. Clin Infect Dis 2019; 68:2036.
  56. Stahlman S, Williams VF, Taubman SB. Incident diagnoses of leishmaniasis, active and reserve components, U.S. Armed Forces, 2001-2016. MSMR 2017; 24:2.
  57. Courtenay O, Quinnell RJ, Garcez LM, Dye C. Low infectiousness of a wildlife host of Leishmania infantum: the crab-eating fox is not important for transmission. Parasitology 2002; 125:407.
  58. Arce A, Estirado A, Ordobas M, et al. Re-emergence of leishmaniasis in Spain: community outbreak in Madrid, Spain, 2009 to 2012. Euro Surveill 2013; 18:20546.
  59. Molina R, Jiménez MI, Cruz I, et al. The hare (Lepus granatensis) as potential sylvatic reservoir of Leishmania infantum in Spain. Vet Parasitol 2012; 190:268.
  60. Alexander B, Maroli M. Control of phlebotomine sandflies. Med Vet Entomol 2003; 17:1.
  61. Dey A, Singh S. Transfusion transmitted leishmaniasis: a case report and review of literature. Indian J Med Microbiol 2006; 24:165.
  62. Antinori S, Cascio A, Parravicini C, et al. Leishmaniasis among organ transplant recipients. Lancet Infect Dis 2008; 8:191.
  63. Herwaldt BL, Juranek DD. Laboratory-acquired malaria, leishmaniasis, trypanosomiasis, and toxoplasmosis. Am J Trop Med Hyg 1993; 48:313.
  64. Meinecke CK, Schottelius J, Oskam L, Fleischer B. Congenital transmission of visceral leishmaniasis (Kala Azar) from an asymptomatic mother to her child. Pediatrics 1999; 104:e65.
  65. Alvar J, Jiménez M. Could infected drug-users be potential Leishmania infantum reservoirs? AIDS 1994; 8:854.
  66. Cruz I, Morales MA, Noguer I, et al. Leishmania in discarded syringes from intravenous drug users. Lancet 2002; 359:1124.
  67. Bates PA, Depaquit J, Galati EA, et al. Recent advances in phlebotomine sand fly research related to leishmaniasis control. Parasit Vectors 2015; 8:131.
  68. Killick-Kendrick R, Rioux JA, Bailly M, et al. Ecology of leishmaniasis in the south of France. 20. Dispersal of Phlebotomus ariasi Tonnoir, 1921 as a factor in the spread of visceral leishmaniasis in the Cévennes. Ann Parasitol Hum Comp 1984; 59:555.
  69. Bora D. Epidemiology of visceral leishmaniasis in India. Natl Med J India 1999; 12:62.
  70. Sen Gupta PC. Return of kala-azar. J Indian Med Assoc 1975; 65:89.
  71. Chowdhury R, Huda MM, Kumar V, et al. The Indian and Nepalese programmes of indoor residual spraying for the elimination of visceral leishmaniasis: performance and effectiveness. Ann Trop Med Parasitol 2011; 105:31.
  72. Coleman M, Foster GM, Deb R, et al. DDT-based indoor residual spraying suboptimal for visceral leishmaniasis elimination in India. Proc Natl Acad Sci U S A 2015; 112:8573.
  73. Poché DM, Garlapati RB, Mukherjee S, et al. Bionomics of Phlebotomus argentipes in villages in Bihar, India with insights into efficacy of IRS-based control measures. PLoS Negl Trop Dis 2018; 12:e0006168.
  74. Garlapati R, Iniguez E, Serafim TD, et al. Towards a Sustainable Vector-Control Strategy in the Post Kala-Azar Elimination Era. Front Cell Infect Microbiol 2021; 11:641632.
  75. Reyburn H, Ashford R, Mohsen M, et al. A randomized controlled trial of insecticide-treated bednets and chaddars or top sheets, and residual spraying of interior rooms for the prevention of cutaneous leishmaniasis in Kabul, Afghanistan. Trans R Soc Trop Med Hyg 2000; 94:361.
  76. Courtenay O, Gillingwater K, Gomes PA, et al. Deltamethrin-impregnated bednets reduce human landing rates of sandfly vector Lutzomyia longipalpis in Amazon households. Med Vet Entomol 2007; 21:168.
  77. Mondal D, Huda MM, Karmoker MK, et al. Reducing visceral leishmaniasis by insecticide impregnation of bed-nets, Bangladesh. Emerg Infect Dis 2013; 19:1131.
  78. Picado A, Singh SP, Rijal S, et al. Longlasting insecticidal nets for prevention of Leishmania donovani infection in India and Nepal: paired cluster randomised trial. BMJ 2010; 341:c6760.
  79. Dinesh DS, Das P, Picado A, et al. Long-lasting insecticidal nets fail at household level to reduce abundance of sandfly vector Phlebotomus argentipes in treated houses in Bihar (India). Trop Med Int Health 2008; 13:953.
  80. Picado A, Singh SP, Vanlerberghe V, et al. Residual activity and integrity of PermaNet® 2.0 after 24 months of household use in a community randomised trial of long lasting insecticidal nets against visceral leishmaniasis in India and Nepal. Trans R Soc Trop Med Hyg 2012; 106:150.
  81. Gavgani AS, Hodjati MH, Mohite H, Davies CR. Effect of insecticide-impregnated dog collars on incidence of zoonotic visceral leishmaniasis in Iranian children: a matched-cluster randomised trial. Lancet 2002; 360:374.
  82. Schreck CE, Kline DL, Chaniotis BN, et al. Evaluation of personal protection methods against phlebotomine sand flies including vectors of leishmaniasis in Panama. Am J Trop Med Hyg 1982; 31:1046.
  83. Medley GF, Hollingsworth TD, Olliaro PL, Adams ER. Health-seeking behaviour, diagnostics and transmission dynamics in the control of visceral leishmaniasis in the Indian subcontinent. Nature 2015; 528:S102.
  84. Addy M, Nandy A. Ten years of kala-azar in west Bengal, Part I. Did post-kala-azar dermal leishmaniasis initiate the outbreak in 24-Parganas? Bull World Health Organ 1992; 70:341.
  85. Napier LE, Das Gupta CR. An epidemiological investigation of kala-azar in a rural area in Bengal. Indian J Med Res 1931; 19:295.
  86. Islam S, Kenah E, Bhuiyan MA, et al. Clinical and immunological aspects of post-kala-azar dermal leishmaniasis in Bangladesh. Am J Trop Med Hyg 2013; 89:345.
  87. Quinnell RJ, Courtenay O. Transmission, reservoir hosts and control of zoonotic visceral leishmaniasis. Parasitology 2009; 136:1915.
  88. Killick-Kendrick R. The race to discover the insect vector of kala-azar: a great saga of tropical medicine 1903-1942. Bull Soc Pathol Exot 2013; 106:131.
  89. Molina R, Ghosh D, Carrillo E, et al. Infectivity of Post-Kala-azar Dermal Leishmaniasis Patients to Sand Flies: Revisiting a Proof of Concept in the Context of the Kala-azar Elimination Program in the Indian Subcontinent. Clin Infect Dis 2017; 65:150.
  90. Mondal D, Bern C, Ghosh D, et al. Quantifying the Infectiousness of Post-Kala-Azar Dermal Leishmaniasis Toward Sand Flies. Clin Infect Dis 2019; 69:251.
  91. Courtenay O, Quinnell RJ, Garcez LM, et al. Infectiousness in a cohort of brazilian dogs: why culling fails to control visceral leishmaniasis in areas of high transmission. J Infect Dis 2002; 186:1314.
  92. Courtenay O, Carson C, Calvo-Bado L, et al. Heterogeneities in Leishmania infantum infection: using skin parasite burdens to identify highly infectious dogs. PLoS Negl Trop Dis 2014; 8:e2583.
  93. Bern C, Courtenay O, Alvar J. Of cattle, sand flies and men: a systematic review of risk factor analyses for South Asian visceral leishmaniasis and implications for elimination. PLoS Negl Trop Dis 2010; 4:e599.
Topic 5690 Version 26.0

References

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟